Mocetinostat
{{Infobox drug | Watchedfields = changed | verifiedrevid = 470603252 | IUPAC_name = N-(2-Aminophenyl)-4-[[[4-[[[[(1E)-2-cyano-1-ethenyl]oxy]methyl]phenyl]amino]methylidene]-2,5-cyclohexadien-1-ylidene]benzamide | image = | tradename = | Drugs.com = | pregnancy_category = | legal_status = Investigational | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 726169-73-9 | ATC_prefix = | ATC_suffix = | PubChem = 9931954 | DrugBank = | ChemSpider = 8107583 | UNII = 7K33JQL57R | KEGG = | ChEMBL = CHEMBL354536 | synonyms = MGCD0103 }}
Mocetinostat is an experimental drug and histone deacetylase inhibitor currently under investigation for its potential use in the treatment of various cancers, including Hodgkin's lymphoma, acute myeloid leukemia (AML), and solid tumors. It is known by its chemical name, N-(2-Aminophenyl)-4-[[[4-[[[[(1E)-2-cyano-1-ethenyl]oxy]methyl]phenyl]amino]methylidene]-2,5-cyclohexadien-1-ylidene]benzamide, and also by its developmental code, MGCD0103.
Mechanism of Action
Mocetinostat functions by inhibiting the activity of certain enzymes known as histone deacetylases (HDACs). These enzymes play a crucial role in the regulation of gene expression by altering the chromatin structure, which can affect cell cycle progression and survival. By inhibiting HDACs, mocetinostat can induce apoptosis (programmed cell death) and inhibit the proliferation of cancer cells.
Clinical Trials
Mocetinostat has been involved in several clinical trials assessing its efficacy and safety. It has been studied as a monotherapy and in combination with other chemotherapy agents. The outcomes of these trials are critical for determining the potential of mocetinostat as a viable therapeutic option in oncology.
Pharmacokinetics
Details on the pharmacokinetics of mocetinostat, such as its bioavailability, metabolism, and excretion, are essential for understanding its behavior in the human body. These factors influence the dosage and administration strategies of the drug.
Regulatory Status
As of the last update, mocetinostat is classified as an investigational drug and has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use. It remains in various phases of clinical trials to establish its safety and efficacy profiles.
Potential Side Effects
Like all therapeutic agents, mocetinostat may cause side effects. The nature and severity of these side effects can vary among individuals and depend on several factors, including the dosage and duration of treatment. Common side effects observed in trials include fatigue, nausea, and changes in blood counts.
Future Prospects
The future development of mocetinostat depends on the outcomes of ongoing and future clinical trials. Positive results could lead to further studies and potentially to regulatory approval for use in specific types of cancer.
Mocetinostat gallery
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD